Pharming Group (Pharming Group) Long-Term Debt

: $136.6 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Pharming Group's Long-Term Debt for the quarter that ended in Dec. 2023 was $136.6 Mil.

Pharming Group's quarterly Long-Term Debt declined from Jun. 2023 ($134.2 Mil) to Sep. 2023 ($129.7 Mil) but then increased from Sep. 2023 ($129.7 Mil) to Dec. 2023 ($136.6 Mil).

Pharming Group's annual Long-Term Debt declined from Dec. 2021 ($139.0 Mil) to Dec. 2022 ($131.6 Mil) but then increased from Dec. 2022 ($131.6 Mil) to Dec. 2023 ($136.6 Mil).

Pharming Group Long-Term Debt Historical Data

The historical data trend for Pharming Group's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

149.73

139.01

131.62

136.60

Pharming Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Debt																131.62	133.58	134.18	129.73	136.60

Pharming Group (NAS:PHAR) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Pharming Group Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Pharming Group's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group (Pharming Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

PHGUF:USA PHARM:Netherlands PHARMa:UK 0QCO:UK PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.